Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRG-1801 in Refractory Lupus Nephritis and IgG4-Related Disease
NCT06497387Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribrecabtagene autoleucel in lupus nephritis (LN) and IgG4-related disease (IgG4-RD), sponsored by Tongji Hospital. Primary endpoints: Safe dose of PRG-1801 infusion up to 24 months and Occurrence of AE after PRG-1801 infusion up to 24 months. Started Jul 2024; status: recruiting.
02
Drugs
ribrecabtagene autoleucel
03
Conditions
lupus nephritis (LN)IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT06497387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497387.